Tatva Chintan Pharma Chem Limited

NSE: TATVA · Unclassified

₹1,605.80-3.59%06 Nov 2026

Ask the data

Instant answers about Tatva Chintan Pharma Chem Limited — computed from its filings, no language model

Market cap₹3,756 cr

Current price₹1,605.80

High / Low₹1,991 / ₹1,052

P/E59.7

P/B4.61

Book value₹348.3

ROE7.7%

ROCE9.2%

Debt / equity0.21

Dividend yield0.06%

EPS (TTM)₹26.89

Face value₹10

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY22	FY23	FY24	FY25	FY26
Revenue	433.6	423.6	393.5	382.7	505.9
EBITDA	108.2	60.6	68.2	34.2	93.2
Operating margin	25.0%	14.3%	17.3%	8.9%	18.4%
Interest	4.8	8.4	6.5	1.3	2.9
Depreciation	8.2	9.6	25.6	27.7	36.9
Profit before tax	104.1	44.8	43.6	7.6	57.0
Tax	8.2	-0.7	13.2	1.9	15.0
Net profit	95.9	45.5	30.4	5.7	42.0
EPS ₹	44.59	20.52	13.26	2.44	17.98
Operating cash flow	20.4	27.8	98.0	24.7	31.5
Capex	89.2	203.1	128.5	76.3	113.8
Dividend paid	0.0	4.4	4.7	4.7	2.3
Total assets	—	756.3	818.7	836.2	1,003.7
Equity	—	514.8	737.1	738.8	781.8

Quarterly performance

last 21 quarters · ₹ crore

showing latest 8 of 21 periods

	JUN '21	SEP '21	DEC '21	MAR '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	106.8	123.6	104.7	98.5	90.1	120.6	124.5	114.4	96.7	84.2	98.3	105.5	83.5	85.9	107.9	116.9	123.5	131.3	134.1	167.1	217.3
Operating profit	25.8	35.9	23.8	21.9	11.2	17.9	16.3	21.3	20.2	11.0	15.6	12.6	5.6	7.1	8.9	17.3	22.2	25.5	28.1	32.3	40.7
Operating margin	24.2%	29.0%	22.7%	22.3%	12.4%	14.8%	13.1%	18.7%	20.9%	13.1%	15.9%	12.0%	6.7%	8.2%	8.3%	14.8%	18.0%	19.4%	21.0%	19.3%	18.7%
Other income	3.0	2.8	4.7	0.3	1.6	1.5	0.8	1.0	0.8	1.2	4.5	1.2	0.4	0.0	0.7	1.2	1.0	1.7	-0.3	2.8	1.8
Interest	2.6	1.2	1.0	1.2	1.4	2.8	3.2	2.9	3.0	0.4	0.2	0.3	0.2	0.4	0.4	0.4	0.5	0.5	1.4	2.1	2.7
Depreciation	1.9	2.1	2.1	2.1	2.3	2.4	2.5	6.0	6.8	6.6	6.2	6.7	6.8	6.9	7.3	9.0	9.1	9.1	9.8	10.6	10.8
Profit before tax	24.3	35.4	25.5	19.0	9.1	14.2	7.8	13.4	11.2	5.2	13.7	6.8	-1.0	-0.2	2.0	9.1	13.7	17.7	16.6	21.1	28.9
Tax	1.1	3.0	2.7	1.5	1.9	2.6	-9.2	3.9	3.4	1.8	4.1	1.6	-0.4	-0.4	1.0	2.5	3.8	2.5	6.3	5.1	7.5
Net profit	23.1	0.0	22.8	17.5	7.1	11.6	16.9	9.5	7.8	3.5	9.6	5.2	-0.7	0.1	1.0	6.7	9.9	15.2	10.3	16.0	21.4
EPS ₹	11.52	15.02	10.29	7.90	3.21	5.24	7.65	4.29	3.43	1.48	4.11	2.23	-0.29	0.06	0.44	2.84	4.24	6.49	4.41	6.83	9.17
Revenue YoY	—	—	—	—	-27.1%	15.2%	26.4%	—	7.3%	-30.2%	-21.1%	-7.8%	-13.6%	2.0%	9.8%	10.8%	47.9%	52.9%	24.4%	43.0%	75.9%
Profit YoY	—	—	—	—	—	-49.1%	-3.2%	—	9.4%	-70.2%	-43.3%	-45.2%	-108.5%	-96.0%	-89.3%	27.6%	—	10728.6%	901.9%	140.3%	116.2%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 15 periods

	MAR '22	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	—	8.8%	6.3%	5.2%	4.1%	3.5%	2.4%	1.9%	0.8%	1.0%	2.4%	4.3%	5.4%	6.6%	7.7%
ROCE	—	8.0%	7.4%	6.0%	6.7%	5.4%	3.4%	2.7%	1.1%	1.5%	3.1%	5.3%	6.6%	8.2%	9.2%
Net margin	14.6%	10.0%	10.1%	9.0%	7.7%	6.8%	4.7%	3.8%	1.5%	1.8%	4.1%	6.8%	8.3%	9.2%	9.7%
EBITDA margin	24.8%	14.8%	16.6%	16.4%	17.3%	15.5%	12.1%	11.0%	8.9%	9.9%	12.8%	15.4%	18.4%	19.4%	19.5%
Debt / equity	—	0.33	0.08	0.08	0.02	0.02	0.02	0.02	0.05	0.05	0.11	0.11	0.15	0.15	0.21
Interest coverage	18.27	5.31	4.90	4.96	7.67	10.45	24.10	18.34	6.88	8.11	15.20	24.58	21.00	16.27	13.54
Asset turnover	—	0.59	0.54	0.50	0.48	0.47	0.46	0.46	0.46	0.47	0.48	0.53	0.50	0.55	0.58

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 9 periods

	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	22.2	22.2	23.4	23.4	23.4	23.4	23.4	23.4	23.4
Other equity / reserves	463.8	492.6	704.0	713.7	714.2	715.4	731.0	758.4	791.3
Total equity	485.9	514.8	727.4	737.1	737.6	738.8	754.4	781.8	814.6
Borrowings	139.7	170.3	61.0	14.3	15.2	36.4	83.0	120.4	170.0
Current liabilities	198.3	236.1	110.0	79.7	67.8	96.0	151.9	213.1	295.5
Non-current liabilities	9.3	5.4	2.8	2.0	1.6	1.4	1.4	8.8	8.6
Total assets	693.6	756.3	840.2	818.7	807.0	836.2	907.7	1,003.7	1,118.7
Property, plant & equipment	160.5	195.8	434.8	426.5	420.9	525.5	509.0	604.1	588.8
Capital work-in-progress	129.4	230.7	19.9	72.9	113.5	21.5	79.9	23.4	42.8
Investments	0.0	0.0	0.0	10.1	0.0	0.0	0.0	4.0	4.0
Inventories	203.0	162.5	143.2	152.8	144.5	133.9	146.0	196.1	248.9
Receivables	58.4	84.4	59.6	69.8	66.2	82.5	101.4	119.0	178.4
Cash & equivalents	67.3	27.4	125.7	35.3	12.2	11.4	12.5	5.8	10.7

Cash flow

annual · ₹ crore · line = free cash flow

	FY22	FY23	FY24	FY25	FY26
Cash from operations	20.4	27.8	98.0	24.7	31.5
Cash from investing	-196.8	-101.1	-120.5	-65.2	-115.8
Cash from financing	235.0	37.8	30.5	16.6	78.9
Capex	89.2	203.1	128.5	76.3	113.8
Free cash flow	-68.8	-175.3	-30.5	-51.6	-82.3
Dividends paid	0.0	4.4	4.7	4.7	2.3

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹588.8 cr53%

CWIP

₹42.8 cr4%

Investments

₹4.0 cr0%

Inventories

₹248.9 cr22%

Receivables

₹178.4 cr16%

Cash & equivalents

₹10.7 cr1%

Other assets

₹45.1 cr4%

Peer comparison

largest in Unclassified · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Avantel Limited	36,86,04,549	138.69	—	1059360.68	0.0%
Ducol Organics And Colours Limited	19,55,275	120.00	—	20089.13	0.0%
Jio Platforms Limited	12,57,181	1,406.40	—	3.57	—
SBI Funds Management Limited	1,01,750	499.55	—	—	—
Tamilnadu Telecommunication Limited	91,314	9.93	—	—	—
Manipal Health Enterprises Limited	76,294	646.70	—	—	—
INDO-MIM Limited	59,042	1,219.50	—	—	—
AvenuesAI Limited	45,138	129.25	153.6	9.51	6.2%
Dhoot Transmission Limited	32,761	1,601.60	—	8.11	—
3M India Limited	31,071	27,570.00	53.8	17.57	32.7%
Tatva Chintan Pharma Chem Limited	3,756	1,605.80	59.7	4.61	7.7%

StoxGud checklist: Neutral setup · 5/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-19.4%

6 months+17.9%

1 year+17.5%

3Y CAGR+3.3%

5Y CAGR-10.2%

10Y CAGR—

50-day avg₹1,721.54

200-day avg₹1,411.82

RSI (14)24

FAQs

What is the share price of Tatva Chintan Pharma Chem Limited?

Tatva Chintan Pharma Chem Limited (TATVA) closed at ₹1,605.80 on NSE on 06 Nov 2026.

What is the market cap of Tatva Chintan Pharma Chem Limited?

₹3,756 crore at the latest close.

What is the P/E ratio of Tatva Chintan Pharma Chem Limited?

59.7, on trailing-twelve-month earnings from its filings.

How fast is Tatva Chintan Pharma Chem Limited growing?

Tatva Chintan Pharma Chem Limited: revenue has compounded at 6.1% a year over three years; net profit at -2.6% a year. Latest-quarter revenue is up 75.9% year on year, profit up 116.2%.

How profitable is Tatva Chintan Pharma Chem Limited?

On a trailing-twelve-month basis return on equity is 7.7%, return on capital employed 9.2%, operating margin 19.5%, net margin 9.7%.

How much debt does Tatva Chintan Pharma Chem Limited have?

Tatva Chintan Pharma Chem Limited is lightly geared: debt to equity is 0.21 with borrowings of ₹170 cr against cash of ₹11 cr (balance sheet of 2026-09-30). Operating profit covers interest 13.5 times.

Financials parsed from Tatva Chintan Pharma Chem Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from JUN '21, annual from FY22, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.